NCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT06572319 2024-08-27
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06492317 2024-07-09
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06439550 2024-06-03
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT05982834 2023-08-09
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Fudan University
Phase 1/2 Unknown
NCT05311189 2022-04-05
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05270889 2022-03-08
Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial
Yonsei University
Phase 2 Unknown
NCT05070598 2021-10-07
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Shengjing Hospital
Phase 2 Unknown